BioAge Ends Phase 2 Trial for Treatment of Obesity

 Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag

Company will evaluate data from patients enrolled to date and share updated plans for azelaprag in Q1 2025

In parallel to evaluating azelaprag, Company will continue to advance earlier platform-derived programs, including IND submission for CNS penetrant NLRP3 inhibitor anticipated in the second half of 2025

https://www.globenewswire.com/news-release/2024/12/06/2993284/0/en/BioAge-Labs-Announces-Discontinuation-of-STRIDES-Phase-2-Clinical-Trial-Evaluating-Azelaprag-in-Combination-with-Tirzepatide-for-the-Treatment-of-Obesity.html